Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;84(16):1479-1489.
doi: 10.1002/pros.24788. Epub 2024 Sep 9.

A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer

Daniel Boiarsky  1 , Alok K Tewari  2 , Doga C Gulhan  3 , Ziad Bakouny  4 , Guruprasad Ananda  5 , Hunter Savignano  2 , Gitanjali Lakshminarayanan  2 , Heather M McClure  2 , Rebecca Silver  2   6 , Toni K Choueiri  2 , Mary-Ellen Taplin  2 , Peter J Park  3 , Jacob E Berchuck  7
Affiliations

A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer

Daniel Boiarsky et al. Prostate. 2024 Dec.

Abstract

Background: The PARP inhibitor (PARPi) olaparib is approved for homologous recombination repair (HRR) gene-altered metastatic castration-resistant prostate cancer (mCRPC). However, there is significant heterogeneity in response to PARPi in patients with mCRPC. Better clinical biomarkers are needed to identify patients likely to benefit from PARPi.

Methods: Patients with prostate adenocarcinoma and panel sequencing at Dana-Farber Cancer Institute were identified. Mutational signature analysis was performed using SigMA to characterize tumors as HRR deficient (HRD). The validity of SigMA to identify patients likely to benefit from olaparib was compared to the current FDA label (presence of a deleterious alteration in one of 14 HRR genes).

Results: 546 patients were identified, of which 34% were HRD. Among patients with HRR gene alterations, only patients with BRCA2 two-copy loss (2CL) were more likely to be HRD compared to patients without HRR gene alterations (74% vs 31%; P = 9.1 × 10-7). 28 patients with mCRPC received olaparib, of which 13 were HRD and 9 had BRCA2 2CL. SigMA improved upon the current FDA label for predicting PSA50 (sensitivity: 100% vs 90%; specificity: 83% vs 44%; PPV: 77% vs 47%; NPV: 100% vs 89%) and rPFS > 6 months (sensitivity: both 92%; specificity: 93% vs 53%; PPV: 92% vs 63%; NPV: 93% vs 89%). On multivariate analysis, incorporating prognostic clinical factors and HR gene alterations, SigMA-predicted HRD independently associated with improved PSA-PFS (HR = 0.086, p = 0.00082) and rPFS (HR = 0.078, p = 0.0070).

Conclusions: SigMA-predicted HRD may better identify patients likely to benefit from olaparib as compared to the current FDA label. Larger studies are needed for further validation.

Keywords: PARP inhibitor; homologous recombination deficiency; metastatic castration‐resistant prostate cancer; mutational signature.

PubMed Disclaimer

References

REFERENCES

    1. Robinson D, Van Allen EM, Wu Y‐M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215‐1228.
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration‐resistant prostate cancer. N Engl J Med. 2020;382:2091‐2102.
    1. Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration‐resistant prostate cancer. N Engl J Med. 2020;383:2345‐2357.
    1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Version 1.2023 [Internet]. Natl Comprehensive Cancer Netw. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
    1. Carreira S, Porta N, Arce‐Gallego S, et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP‐B trial. Cancer Discov. 2021;11:2812‐2827.

MeSH terms

LinkOut - more resources